From Molecule to Market: Simplifying the Characterization of Antibody-Drug Conjugates (ADCs) Webinar
Overview
Antibody-drug conjugates (ADCs) are among the fastest growing class of biologics and are developed as a combination of monoclonal antibodies (mAbs) and highly potent cytotoxic molecules (drugs). The antibody, in addition to its own biological specificity through its paratope, has the function of a targeted transporting tool of the drug to the targeted cell. The conjugated molecules or particles typically have cytotoxic activity and thus increase the efficiency of the antibody by an additional mechanism, leading to increased death of cells carrying the target antigen.
Conjugation of these drugs to antibodies, however, increases structural complexity which triggers the need for improved characterization methods. Common analytical technologies for characterization of ADCs, such as liquid chromatography, electrophoresis, and mass spectrometry, are useful in enabling the optimization of ADCs but need to be complemented with technologies that can add biophysical and functional information.
This webinar will demonstrate the use of Octet® Bio-Layer Interferometry (BLI) platform in combination with the iQue® Advanced Flow Cytometry Platform to characterize and compare the drug trastuzumab to the trastuzumab-containing reference medicinal products Kadcyla® and Enhertu®.
- Document type: Webinar
- Watch time: 32 minutes
Learning objectives:
- Assay considerations for ADCs characterization
- Need for complimentary techniques for selection of optimal drug candidates
Webinar Speakers
David Apiyo, Ph.D.
Senior Manager, Applications
Sartorius
David is a Senior Manager of Applications at Sartorius, focused on Octet® label-free detection platforms and applications. In this role, he leads a team of Applications Managers and is responsible for the strategic direction of the GMP/GxP and bioprocessing vertical markets.
David started out as a Field Applications Scientist in 2011 and transitioned to the marketing applications team in 2015. Prior to this, David worked as a Senior Development Scientist, R&D department, at Beckman Coulter where he was involved in the development and validation of protein and antibody conjugate chemistries.
David obtained his Ph.D. in Protein Chemistry from Tulane University, New Orleans.